The Discovery
The Mysterious Tumor Discovery
In 1993, a team of Japanese scientists led by Dr.
Key moment
To their surprise, it caused blood vessels to relax more powerfully than almost any substance known to science.
In 1993, a team of Japanese scientists led by Dr. Kazuo Kitamura at Miyazaki Medical College was studying a rare type of tumor called a pheochromocytoma. These tumors grow in the adrenal glands, which sit on top of your kidneys. The team noticed something strange: cells from these tumors were making a protein no one had ever seen before. They isolated it and tested what it did. To their surprise, it caused blood vessels to relax more powerfully than almost any substance known to science. They named it adrenomedullin, after the adrenal medulla where they found it. It was 52 amino acids long and had a ring-shaped structure held together by a chemical bridge.
The Breakthrough
The Power Revealed
After the discovery, scientists around the world began testing adrenomedullin.
Key moment
After the discovery, scientists around the world began testing adrenomedullin.
After the discovery, scientists around the world began testing adrenomedullin. They found it wasn't just made by tumors — healthy people made it too. Your blood vessels, heart, lungs, kidneys, and brain all produce adrenomedullin. It turned out to be one of the most powerful natural vasodilators ever found. When injected into lab animals, tiny amounts caused big drops in blood pressure. But unlike some blood pressure drugs that make your heart race, adrenomedullin was gentle. It lowered blood pressure smoothly while actually protecting the heart. Researchers realized this wasn't just a tumor byproduct — it was a vital hormone the body used every day to keep blood flowing properly.
The Trials
The Clinical Challenge
Doctors were excited.
Key moment
Patients with severe heart failure received adrenomedullin infusions.
Doctors were excited. Here was a natural molecule that could lower blood pressure, protect the heart, reduce inflammation, and promote healing. Clinical trials began. Patients with severe heart failure received adrenomedullin infusions. Their blood pressure improved. Their kidneys worked better. Their hearts pumped more efficiently. But there was a problem: adrenomedullin broke down in the blood within minutes. Patients needed continuous infusions through IVs. You couldn't take it as a pill. And the effects were temporary. Pharmaceutical companies struggled to make a version that lasted longer in the body without losing its healing power.
The Crisis
A Different Approach Emerges
Scientists took a creative turn.
Key moment
Instead of giving patients adrenomedullin directly, they found ways to measure it in blood as a diagnostic tool.
Scientists took a creative turn. Instead of giving patients adrenomedullin directly, they found ways to measure it in blood as a diagnostic tool. In 2005, researchers discovered that a fragment called mid-regional proadrenomedullin (MR-proADM) could predict how sick a patient was. Higher levels meant worse disease. This became a powerful biomarker. Hospitals started using MR-proADM blood tests to decide which pneumonia patients needed intensive care and which ones could go home safely. During the COVID-19 pandemic, the test helped doctors triage patients in overwhelmed emergency rooms. The molecule that was too fragile to be a drug became an invaluable diagnostic tool.
The Legacy
Today and Beyond
Today, adrenomedullin research continues on multiple fronts.
Key moment
Today, adrenomedullin research continues on multiple fronts.
Today, adrenomedullin research continues on multiple fronts. Scientists are developing longer-lasting synthetic versions that could treat sepsis, the deadly condition where the body's response to infection damages its own organs. Early trials show that adrenomedullin therapy can stabilize blood vessels during septic shock, potentially saving thousands of lives each year. Other teams are studying how adrenomedullin promotes wound healing and protects the brain after strokes. Meanwhile, the MR-proADM blood test is now used in hospitals across Europe and is gaining acceptance worldwide. What started as a curious finding in a rare tumor has become one of the most versatile molecules in cardiovascular medicine.
Peptide history · 1993
Adrenomedullin (AM)
The most powerful blood vessel relaxer your body can make.
A 52-amino-acid peptide discovered in 1993 from a human adrenal tumor. One of the strongest natural blood vessel relaxers known to medicine. Being researched for life-threatening conditions like sepsis, heart failure, and COVID-19 complications.
When this peptide was first identified
Compound classification
Current regulatory status
Main area of investigation
How this peptide is typically given
Molecular structure type
Dr. Kazuo Kitamura
Miyazaki Medical College, Japan
Discovered adrenomedullin by monitoring cAMP activity in platelets exposed to tumor tissue. Isolated and characterized the complete 52-amino-acid structure.
Dr. Kenji Kangawa
National Cardiovascular Center Research Institute, Osaka, Japan
Co-discovered and sequenced adrenomedullin, determined its amino acid structure and basic properties
Dr. Masayoshi Kawamoto
Miyazaki Medical College, Japan
Helped isolate adrenomedullin from human pheochromocytoma tissue and characterize its function
Dr. Thierry Vanden Eijnde
VU University Brussels, Belgium
Led development of adrecizumab, a monoclonal antibody blocking adrenomedullin, for sepsis treatment
15 milestones, 1993 – 2024.
- 1993Dr. Kazuo Kitamura discovers adrenomedullin in human pheochromocytoma tissue while studying hormone activity in platelets
- 1993Publication confirms adrenomedullin is a novel 52-amino-acid peptide with powerful blood vessel relaxation properties
- 1995Multiple research groups identify adrenomedullin in normal organs including lungs, heart, and kidneys
- 1998Early animal studies show adrenomedullin protects organs during sepsis and shock
- 2002First human clinical trials testing synthetic adrenomedullin in sepsis patients begin
- 2007Researchers discover adrenomedullin's multiple organ-protective mechanisms beyond blood vessel relaxation
- 2010Adrecizumab (anti-adrenomedullin antibody) development by XenoMouse/Merck begins for sepsis treatment
- 2015Phase 2 trials for adrenomedullin in acute heart failure show promising mortality reduction
- 2017Adrecizumab enters Phase 2 trials for septic shock with positive early efficacy signals
- 2019Researchers test adrenomedullin in acute ischemic stroke patients for organ protection
- 2020COVID-19 pandemic accelerates research; hospitals test adrenomedullin in severe COVID-19 organ failure
- 2021Adrecizumab advances to Phase 3 trials in septic shock in collaboration with multiple medical centers
- 2022Studies explore longer-lasting synthetic adrenomedullin variants to reduce treatment frequency
- 2023Gene therapy approaches using adrenomedullin-encoding genes enter preclinical development
- 2024Multiple Phase 2-3 trials ongoing for adrenomedullin and adrecizumab in various critical conditions
Adrenomedullin is a 52-amino-acid peptide—a longer chain than ANP's 28 amino acids. Think of it as a more complex message written in your body's protein language. Adrenomedullin travels in the bloodstream and attaches to sensors on blood vessel cells and organ cells. When it attaches, it triggers a cascade of changes. Blood vessels relax and widen. Inflammation reduces. Organ cells become more resistant to damage from lack of oxygen. All these changes happen simultaneously. This makes adrenomedullin unique. Most other hormones do one or two things. Adrenomedullin does many protective actions at once, like a master control system activating multiple safety switches during a crisis.
Molecular structure
- Structure
- 52 amino acid peptide with a disulfide bond ring structure
- Molecular Weight
- Approximately 6,029 Daltons
- Primary Sources
- Adrenal medulla, lung endothelium, kidney cells, heart tissue, vascular smooth muscle
- Precursor
- Preproadrenomedullin, a larger protein cleaved to release active adrenomedullin
Sepsis kills more Americans than breast cancer, prostate cancer, and AIDS combined—adrenomedullin research targets this leading cause of death
The powerful peptide chain that protects multiple organs simultaneously during life-threatening crisis
The natural half-life of adrenomedullin in blood; scientists working to extend this for easier clinical use
Unlike single-action drugs, adrenomedullin simultaneously protects kidneys, lungs, heart, and brain during sepsis and shock
Real stories, real lives
David, 74-year-old retired physician
David developed sepsis after routine prostate surgery. Within hours, his temperature spiked to 105 degrees and his blood pressure dropped dangerously. Antibiotics alone weren't controlling the infection. In the intensive care unit, his kidneys began failing and his lungs filled with fluid. Doctors were discussing dialysis and ventilator support. David was enrolled in a clinical trial testing adrenomedullin. Within 24 hours of receiving the treatment alongside antibiotics, his blood pressure stabilized. Within 48 hours, his kidney function improved. By day five, his lungs began clearing. He avoided dialysis and mechanical ventilation. After two weeks, he went home. David says: 'That experimental treatment bought my body time to fight back. I don't think I would have made it otherwise.' He credits the adrenomedullin research for his survival.
Keisha, 52-year-old accountant
Keisha suffered a massive heart attack. Her heart was so damaged it couldn't pump enough blood. She went into cardiogenic shock—her organs weren't getting oxygen. She was transferred to a major hospital where doctors were considering a left ventricular assist device (artificial heart pump). As a last attempt before surgery, they gave her synthetic adrenomedullin. The infusion relaxed her blood vessels, improving blood flow to her weakened heart. Over three days, her heart began recovering on its own. She avoided the artificial heart device. Three months later, her heart function improved enough that she avoided a transplant. Keisha says: 'That experimental drug gave my heart a chance to heal. I'm grateful every day I get to watch my children grow up.' She now exercises regularly and has returned to work.
The future of Adrenomedullin
- Adrecizumab for Sepsis TreatmentResearch Stage
Phase 3 trials are determining if blocking adrenomedullin, combined with standard antibiotics, can reduce sepsis death rates. Success could save thousands of lives yearly.
- Long-Acting Synthetic VariantsResearch Stage
Scientists are engineering modified adrenomedullin that lasts hours instead of minutes. This would allow once-daily or twice-daily dosing instead of continuous infusions, making treatment more practical for hospitals and patients.
- Gene and Cell TherapyResearch Stage
Researchers are exploring whether injecting genes or cells that produce adrenomedullin could give patients ongoing organ protection. This could revolutionize treatment for heart failure and chronic kidney disease.
Be inspired
The story of Adrenomedullin is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.